Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2020-03-03 6-K ANNUAL FINANCIAL REPORT View Document
2020-03-02 6-K TOTAL VOTING RIGHTS View Document
2020-03-02 6-K ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH ATNAHS PHARMA FOR ESTABLISHED HY View Document
2020-02-27 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-02-25 6-K ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIK View Document
2020-02-19 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-02-14 6-K AZN: FULL-YEAR AND Q4 2019 RESULTS View Document
2020-02-07 4 4 View Document
2020-02-07 3 3 View Document
2020-02-07 SC 13D SC 13D View Document
2020-02-06 EFFECT View Document
2020-02-05 SC 13G/A View Document
2020-02-03 6-K TOTAL VOTING RIGHTS View Document
2020-01-30 SC 13G SC 13G View Document
2020-01-27 SC 13G/A SEC SCHEDULE 13G View Document
2020-01-27 6-K PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP View Document
2020-01-27 6-K ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN View Document
2020-01-27 6-K BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE View Document
2020-01-27 6-K ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES View Document
2020-01-22 F-6 FORM F-6 View Document
2020-01-21 6-K LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATED View Document
2020-01-21 6-K IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CAN View Document
2020-01-13 6-K LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MA View Document
2020-01-13 6-K UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA View Document
2020-01-06 6-K LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA View Document
2020-01-06 6-K FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED View Document
2020-01-02 6-K TOTAL VOTING RIGHTS View Document
2019-12-30 6-K LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA- View Document
2019-12-23 6-K ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP View Document
2019-12-23 6-K ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB View Document
2019-12-20 6-K ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO View Document
2019-12-17 6-K FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCER View Document
2019-12-16 6-K SEROQUEL RIGHTS AGREEMENT COMPLETE: EUROPE, RUSSIA View Document
2019-12-12 6-K IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALL View Document
2019-12-11 6-K TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASE View Document
2019-12-05 6-K LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADV View Document
2019-12-03 6-K ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN THE US AND CANADA View Document
2019-12-02 6-K BLOCK LISTING INTERIM REVIEW View Document
2019-12-02 6-K TOTAL VOTING RIGHTS View Document
2019-11-29 6-K IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVE View Document
2019-11-21 6-K CALQUENCE APPROVED IN THE US FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEM View Document
2019-11-15 6-K QTRILMET APPROVED IN THE EU FOR TREATMENT OF T2D View Document
2019-11-14 6-K FDA ACCEPTS REGULATORY SUBMISSION FOR SELUMETINIB View Document
2019-11-12 6-K ANIFROLUMAB DEMONSTRATED SUPERIORITY ACROSS MULTIPLE EFFICACY ENDPOINTS IN PATIE View Document
2019-11-12 6-K ROXADUSTAT PHASE III PROGRAMME POOLED ANALYSES SHOWED POSITIVE EFFICACY AND NO I View Document
2019-11-08 6-K ROXADUSTAT SIGNIFICANTLY INCREASED HAEMOGLOBIN LEVELS FOR CHRONIC KIDNEY DISEASE View Document
2019-11-08 F-3ASR FORM F-3ASR View Document
2019-11-06 6-K CALQUENCE DATA TO SHOW IMPROVED PROGRESSION-FREE SURVIVAL IN PHASE III FRONT-LIN View Document
2019-11-01 6-K TOTAL VOTING RIGHTS View Document
2019-10-30 6-K ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN EUROPE AND RUSSIA View Document
2019-10-28 6-K IMFINZI AND IMFINZI PLUS TREMELIMUMAB DELAYED View Document
2019-10-25 SC 13D SC 13D View Document
2019-10-24 6-K ASTRAZENECA YEAR-TO-DATE AND Q3 2019 RESULTS View Document
2019-10-21 6-K FARXIGA APPROVED IN THE US TO REDUCE THE RISK OF HOSPITALISATION FOR HEART FAILU View Document
2019-10-17 6-K TRASTUZUMAB DERUXTECAN GRANTED FDA PRIORITY REVIEW FOR TREATMENT OF PATIENTS WIT View Document
2019-10-09 4 FORM 4 SUBMISSION View Document
2019-10-09 3/A FORM 3/A SUBMISSION View Document
2019-10-04 6-K HOLDING(S) IN COMPANY View Document
2019-10-04 6-K HOLDING(S) IN COMPANY View Document
2019-10-04 6-K FASENRA APPROVED IN THE US FOR SELF-ADMINISTRATION View Document
2019-10-03 6-K DIRECTOR DECLARATION View Document
2019-10-02 3 FORM 3 SUBMISSION View Document
2019-10-01 6-K TOTAL VOTING RIGHTS View Document
2019-10-01 6-K ASTRAZENECA DIVESTS RIGHTS FOR LOSEC TO CHEPLAPHAR View Document
2019-10-01 6-K UPDATE ON US REGULATORY REVIEW OF PT010 IN COPD View Document
2019-09-30 6-K LYNPARZA MORE THAN DOUBLED THE TIME WITHOUT RADIOGRAPHIC DISEASE PROGRESSION IN View Document
2019-09-30 6-K LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS View Document
2019-09-30 6-K TAGRISSO IS THE ONLY 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CAN View Document
2019-09-23 6-K QTRILMET RECOMMENDED FOR APPROVAL IN EU BY CHMP View Document
2019-09-18 25-NSE View Document
2019-09-18 6-K ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINA View Document
2019-09-09 6-K IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMP View Document
2019-09-04 6-K TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CE View Document
2019-09-03 6-K TOTAL VOTING RIGHTS View Document
2019-09-03 6-K DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUC View Document
2019-09-03 6-K BRILINTA REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ART View Document
2019-08-29 6-K ANIFROLUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN SYSTEMIC LUPUS ERYTHEMATOS View Document
2019-08-28 6-K BREZTRI AEROSPHERE PHASE III ETHOS TRIAL MET ITS PRIMARY ENDPOINT IN CHRONIC OBS View Document
2019-08-28 6-K FASENRA GRANTED US ORPHAN DRUG DESIGNATION FOR EOSINOPHILIC OESOPHAGITIS View Document
2019-08-22 6-K ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPEND View Document
2019-08-22 6-K ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEW View Document
2019-08-21 6-K UPDATE ON THE PHASE III NEPTUNE TRIAL View Document
2019-08-20 6-K FARXIGA MET PRIMARY ENDPOINT IN LANDMARK PHASE III View Document
2019-08-19 6-K DIRECTORATE CHANGE View Document
2019-08-14 6-K CALQUENCE GRANTED US BREAKTHROUGH THERAPY DESIGNATION View Document
2019-08-14 6-K LYNPARZA PHASE III PAOLA-1 TRIAL MET PRIMARY ENDPOINT View Document
2019-08-09 6-K TAGRISSO SIGNIFICANTLY IMPROVES OVERALL SURVIVAL View Document
2019-08-07 6-K LYNPARZA PHASE III PROFOUND TRIAL IN HRR* View Document
2019-08-05 6-K FORXIGA LABEL UPDATED IN THE EU IN TYPE-2 DIABETES View Document
2019-08-01 6-K TOTAL VOTING RIGHTS View Document
2019-07-25 6-K 6-K View Document
2019-07-15 6-K UPDATE ON US REGULATORY DECISION FOR FARXIGA View Document
2019-07-12 6-K IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCER View Document
2019-07-01 6-K FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELF View Document
2019-07-01 6-K TOTAL VOTING RIGHTS View Document
2019-07-01 6-K FORXIGA RECEIVES POSITIVE EU CHMP OPINION FOR View Document
2019-06-27 11-K View Document
2019-06-27 6-K IMFINZI IMPROVES OVERALL SURVIVAL AT INTERIM View Document
2019-06-19 6-K BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTI View Document
2019-06-19 6-K LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVA View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299